Economic evaluation of chronic hepatitis C treatment by interferon-ribavirin combination therapy in Belgium

Acta Gastro-Enterologica Belgica

Volumn 65, Issue 4, 2002, Pages 233-236

  Delwaide, Jean ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cost effectiveness; Health care; Hepatitis C; Interferon alpha; Qaly; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

BELGIUM; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEPATITIS C; HUMAN; PREVALENCE;

ANTIVIRAL AGENTS; BELGIUM; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; RIBAVIRIN; TREATMENT OUTCOME;

EID: 0036826026     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. BEUTELS M., VAN DAMME P., AELVOET W., DESMYTER J., DONDEYNE F., GOILAV C., MAK R., MUYLLE L., PIERARD D., STROOBANT A., VAN LOOCK F., WAUMANS P., VRANCKX R. Prevalence of hepatitis A, B, and C in the Flemish population. European Journal of Epidemiolog, 1997, 13: 275-280.
2. DELWAIDE J., BOURGEOIS N., COLLE I., ROBAEYS G. Risk factors for hepatitis C: past, present and future. Acta Gastroenterol. Belg., 2002, 65 : 87-89.
3. FATTOVITCH G., GUISTINA G., DEGAS F. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow up study of 384 patients. Gastroenterology, 1997, 112: 463-472.
4. YANO M., KUMUDA H., KAGE M., IKEDA K., SHIMAMATSU K., INOUE O., HASHIMOTO E., LEFKOWITCH J., LUDWIG J., OKUDA K. The long-term pathological evolution of chronic hepatitis C. Hepatology, 1996, 23: 1334-1340.
5. MC HUTCHISON J., GORDON G., SCHIFF E., SHIFFMAN M., LEE W., RUSTGI V., GOODMAN Z., LING M., CORT S., ALBRECHT J. for the Hepatitis Interventional Therapy Group. Interferon alpha2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med., 1998, 339 (21): 1485-1492.
6. POYNARD T, MARCELLIN P., LEE S., NIEDERAU C., MINUK G., IDEO G., BAIN V., HEATCOTE J., ZEUZEM S., TREPO C., ALBRECHT J., for the International Hepatitis Interventional Therapy Group, Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic hepatitis infection with hepatitis C virus. Lancet, 1998. 352: 1426-1432.
7. KLETER B., BROUWER J., NEVENS F., VAN DOORN L., ELEWAUT A., VERSIECK J., MICHIELSEN P., HAUTEKEETE M., CHAMULEAU R., BRENARD R., BOURGEOIS N., ADLER M., QUINT W., BRONK-HORST C., HEIJTINK R., HOP W., FEVERY J., SCHALM S., the Benelux Study Group on Treatment of Chronic Hepatitis C. Hepatitis C virus genotypes: epidemiological and clinical associations. Liver, 1998, 18: 32-38.
8. SCHALM S., WEILAND O., HANSEN B., MILELLA M., LAI M., HOLLANDER A., MICHIELSEN P., BELLOBUONO A., CHEMELLO L., PASTORE G., CHEN D., BROUWER J., and the EUROHEP study group for viral hepatitis. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology, 1999, 117: 408-413.
9. EASL International Consensus Conference on Hepatitis C. Consensus statement. J. Hepatol., 1999, 30: 956-961.
10. WONG J., POYNARD T., LING H., ALBRECHT J., PAUKER S. on behalf of the International Hepatitis Interventional Therapy Group. Cost-effectiveness of 24 or 48 weeks of interferon alpha 2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am. J. Gastroenterol., 2000, 95: 1524-1530.
11. YOUNOSSI Z., SINGER M., MCHUTCHISON J., SHERMOCK K. Cost-effectiveness of interferon alpha 2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology, 1999, 30: 1318-1324.
12. FLACK-YTTER Y., KALE H., MULLEN K., SARBAH S., SORESCU L., MC CULLOUGH A. Surprinsingly small effect of antiviral treatment in patients with hepatitis C. Ann. Intern. Med., 2002. 136: 288-292.
13. MANNS M., MC HUTCHISON J., GORDON S., RUSTGI V., SHIFFMAN M., REINDOLLAR R., GOODMAN Z., KOURY K., LING M., ALBRECHT J., and the International Interventional Therapy Group. Lancet, 2001, 358: 958-965.
14. WONG J., NEVENS F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol. Belg., 2002, 65: 100-111.